Santen Pharmaceutical Co., Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. It offers various pharmaceutical products to treat glaucoma and ocular hypertension, such as DE-111, which is in Phase III clinical trial; DE-117 in Japan; DE-126 that is in Phase IIb clinical trial; DE-128 in Europe, as well as is in Phase II/III clinical trial in the United States; and DE-130A that is in Phase III clinical trial. In addition, the company provides DE-114A to treat allergic conjunctivitis; DE-076C for the treatment of vernal keratoconjunctivitis; and DE-109, which is in Phase III clinical trial to treat uveitis. Further, it offers DE-127 to treat myopia, which is in Phase II/III clinical trial in Japan, as well as is in Phase III in Asia; DE-089C, which has completed Phase III clinical trials for the treatment of dry eye; and STN1013400, which is in Phase I clinical trials for the treatment of myopia. Additionally, the company offers over-the-counter pharmaceutical products. The company was formerly known as Santendo Pharmaceutical Co., Ltd. and changed its name to Santen Pharmaceutical Co., Ltd. in 1958. Santen Pharmaceutical Co., Ltd. was founded in 1890 and is headquartered in Osaka, Japan.
Revenue of Santen Pharmaceutical Co., Ltd. (4536.T)
Revenue in 2023 (TTM): $2 B
According to Santen Pharmaceutical Co., Ltd.'s latest financial reports the company's current revenue (TTM) is $2 B. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Santen Pharmaceutical Co., Ltd.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $2 B | $1.09 B | $465.09 M | $248.53 M | $176.81 M |
| 2022 | $1.85 B | $1.1 B | $85.93 M | $-38,484,536 | $-99,201,043 |
| 2021 | $1.77 B | $1.04 B | $357.57 M | $236.36 M | $180.63 M |
| 2020 | $1.66 B | $1 B | $203.57 M | $82.41 M | $45.33 M |
| 2019 | $1.6 B | $973.72 M | $338.84 M | $212.97 M | $156.74 M |
| 2018 | $1.55 B | $950.75 M | $378.06 M | $286.14 M | $211.99 M |
| 2017 | $1.49 B | $919.57 M | $335.74 M | $260.55 M | $234.01 M |
| 2016 | $1.32 B | $823.78 M | $287.15 M | $211.18 M | $153 M |
| 2015 | $1.3 B | $812.71 M | $599.27 M | $527.4 M | $354.21 M |
| 2014 | $1.07 B | $699.86 M | $286.03 M | $238 M | $159.49 M |
| 2013 | $986.59 M | $600.99 M | $212.48 M | $178.47 M | $113.54 M |
| 2012 | $790.17 M | $514.75 M | $191.77 M | $169.83 M | $109.63 M |
| 2011 | $759.31 M | $524.48 M | $204.08 M | $184.43 M | $113.88 M |
| 2010 | $735.39 M | $506.86 M | $228.92 M | $206.22 M | $141.57 M |
| 2009 | $733.95 M | $503.6 M | $218.18 M | $189.87 M | $124.25 M |
| 2008 | $674.38 M | $435.82 M | $134.1 M | $105.01 M | $67.18 M |
| 2007 | $686.16 M | $443.85 M | $168.7 M | $135.93 M | $83.95 M |
| 2006 | $666.86 M | $431.38 M | $170.04 M | $139.62 M | $87.25 M |
| 2005 | $653 M | $423.82 M | $174.46 M | $134.99 M | $86.42 M |
| 2004 | $615.17 M | $391.46 M | $157.74 M | $122.35 M | $73.15 M |